Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032809 | 0.88 | NPBWR1 (0.40) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL22032799 | 0.88 | PRMT1 (0.39) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL22032810 | 0.87 | KMT2A (0.37) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL19781136 | 0.86 | BCL2 (0.38) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL19781603 | 0.84 | PRMT1 (0.39) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL22032829 | 0.83 | IDH1 (0.38) | KMT2ABCL2MDM2MCL1KDM4E | |
| SCHEMBL19781572 | 0.80 | MCL1 (0.41) | PRMT1FGFR1BCL2MDM2MCL1 | |
| SCHEMBL22032819 | 0.78 | PRMT1 (0.39) | PRMT1KMT2ACACNA2D1CACNA2D2FGFR1 | |
| SCHEMBL19781253 | 0.77 | FGFR1 (0.60) | FGFR1 | |
| SCHEMBL22071833 | 0.77 | PRMT1 (0.38) | PRMT1KMT2AFGFR1BCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | PRMT1 2276/4885KMT2A 1651/4885CACNA2D1 2472/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | PRMT1 2223/4885KMT2A 1493/4885CACNA2D1 2502/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | PRMT1 2223/4885KMT2A 1493/4885CACNA2D1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.